News

Clinical trial confirms immune enhancing effect of Probi Defendum

15 Feb 2018

Probi's largest clinical trial ever, focused on probiotic immune health, has recently been completed and is said to confirm the strong clinical immune enhancing effect of Probi Defendum.

Probi's largest clinical trial ever, focused on probiotic immune health, has recently been completed. The study included over 900 subjects and was carried out over a period of three winter seasons. The randomized, double-blind, placebo-controlled trial is said to confirm the strong clinical immune enhancing effect of Probi Defendum. The company claims that the study proves Probi Defendum protects against recurrent colds in addition to shedding some light on the mechanism of action behind the effect.

Probi Defendum, a probiotic immune concept based on the combination of Probi’s patented probiotic strains, Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 has in previous clinical studies shown strong immune enhancing effects.

Probi Defendum was given once daily for 12 weeks and common colds were used as a model to examine effects on the immune system.

The results from the study are said to show that Probi Defendum significantly decreases recurrent common colds. In addition, in subjects not experiencing a common cold, an activation of the immune system was apparent already after two weeks of intake of Probi Defendum. Moreover, there was a reduced overall severity of common cold symptoms with Probi Defendum compared to placebo during the first season.

“We are proud to conclude that our largest clinical trial so far has successfully confirmed earlier clinical results. Interestingly, in subjects that did not experience any viral infection during the study period, there was an activation of the immune system measured already after 2 weeks of Probi Defendum intake, indicating an alert and resilient immune system.” said Peter Nählstedt, CEO of Probi.

According to Probi, immune health is the second largest health area for probiotics and Probi Defendum is presently sold in several geographical markets. The new clinical data will strengthen the Probi Defendum concept even further, the company says, and support existing products in the consumer market. It will also create opportunities for new launches by new and existing customers aiming to extend a probiotic gastro position into new health areas, both within the consumer healthcare and the functional food segment.